Home » Stocks » Akero Therapeutics

Akero Therapeutics, Inc. (AKRO)

Stock Price: $26.26 USD 0.00 (0.00%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
After-hours: $36.77 +10.51 (40.02%) Oct 27, 5:55 PM

Stock Price Chart

Key Info

Market Cap 911.24M
Revenue (ttm) n/a
Net Income (ttm) -59.26M
Shares Out 34.70M
EPS (ttm) -2.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $26.26
Previous Close $26.26
Change ($) 0.00
Change (%) 0.00%
Day's Open 26.34
Day's Range 25.94 - 26.83
Day's Volume 104,380
52-Week Range 10.78 - 41.16

More Stats

Market Cap 911.24M
Enterprise Value 808.41M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 34.70M
Float 17.47M
EPS (basic) -1.79
EPS (diluted) -2.08
FCF / Share -2.05
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.36M
Short Ratio 6.88
Short % of Float 7.77%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 8.64
Revenue n/a
Operating Income -61.36M
Net Income -59.26M
Free Cash Flow -58.76M
Net Cash 102.83M
Net Cash / Share 2.96
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -27.67%
ROE -45.23%
ROIC -138.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$60.00*
(128.48% upside)
Low
45.0
Current: $26.26
High
79.0
Target: 60.00
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue---
Operating Income-45.65-13.78-4.56
Net Income-43.76-81.71-4.56
Shares Outstanding15.070.10-
Earnings Per Share-2.90-795.28-
Operating Cash Flow-35.63-4.63-4.38
Free Cash Flow-35.63-4.63-4.38
Cash & Equivalents13675.980.62
Net Cash / Debt13675.980.62
Assets13877.150.66
Liabilities9.392.345.22
Book Value129-49.92-4.56
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Akero Therapeutics, Inc.
Country United States
Employees 13
CEO Andrew Cheng

Stock Information

Ticker Symbol AKRO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AKRO
IPO Date June 20, 2019

Description

Akero Therapeutics, a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.